Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection

Kwon, Hyuk‐Chan; Kim, Min Chan; Kim, Ki Han; Jang, Jin Seok; Oh, Sung Yong; Kim, Sung-Hyun; Kwon, Kee Hwan; Lee, Suee; Lee, Hyung Sik; Kim, Hyojin

doi:10.1111/j.1743-7563.2010.01331.x

Cited by 55 publications

(78 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On study entry, all patients were required to have an Eastern Cooperative Oncology Group performance status <2. All studies required extensive lymph node dissections or the involvement of experienced surgeons (defined as performing a minimum of 20 operations for gastric cancer per year) [17,18,19,20,21,22]. Only one study enrolled patients with D0 lymphadenectomies; we did not account for this difference.…”

Section: Resultsmentioning

confidence: 99%

“…CT-based treatment-planning systems and 3D-conformal techniques were employed. All comparisons reported are for chemotherapy versus concurrent chemoradiation therapy [17,18,19,20,21,22]. …”

Section: Resultsmentioning

confidence: 99%

“…Five of the six trials found no statistically significant differences in toxicities between the chemoradiation and chemotherapy arms [17,18,19,20,22]. Yu et al [21] reported a higher rate of grade 1-2 anorexia (73.5 vs. 44.1%, p = 0.014) and grade 1-2 neutropenia (70.6 vs. 44.1%, p = 0.027) with the addition of radiation therapy.…”

Section: Resultsmentioning

confidence: 99%

“…Yu et al [21] reported a higher rate of grade 1-2 anorexia (73.5 vs. 44.1%, p = 0.014) and grade 1-2 neutropenia (70.6 vs. 44.1%, p = 0.027) with the addition of radiation therapy. There were no differences in treatment-related deaths between the two groups in any study [17,18,19,20,21]. Specifically, only two treatment-related deaths occurred, with one in each arm [20].…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Chemoradiation Therapy versus Chemotherapy Alone for Gastric Cancer after R0 Surgical Resection: A Meta-Analysis of Randomized Trials

et al. 2014

View full text Add to dashboard Cite

Objective: Current national guidelines include category 1 recommendations for perioperative chemotherapy or adjuvant chemoradiation with surgical resection for patients with stage IB-IIIB gastric cancer. We conducted a meta-analysis of randomized trials in which chemotherapy was prospectively tested against chemoradiation with surgical resection. Methods: We electronically searched PubMed and EMBASE for randomized, controlled clinical trials involving patients with gastric adenocarcinoma, status post-R0 resection. The interventions compared were adjuvant chemotherapy versus chemoradiation, with any chemotherapy regimen. The primary outcomes of interest were disease-free survival and overall survival. The Mantel-Haenszel random-effects model was used to calculate effect sizes. Results: Six trials that included 1,171 patients were evaluated; 599 were randomized to adjuvant chemoradiation and 572 to chemotherapy alone. Chemoradiation was associated with a significant increase in disease-free survival (odds ratio 1.48, 95% confidence interval 1.08-2.03) when compared to chemotherapy alone. However, there was no significant difference in overall survival (odds ratio 1.27, 95% confidence interval 0.95-1.71). Five trials found no statistically significant differences in toxicities between the two groups. Conclusion: In patients with gastric cancer status post-R0 resection, adjuvant chemoradiation was associated with higher disease-free survival when compared to chemotherapy alone. It remains appropriate to design trials testing new systemic agents with radiotherapy.

show abstract

Section: Resultsmentioning

confidence: 99%

“…CT-based treatment-planning systems and 3D-conformal techniques were employed. All comparisons reported are for chemotherapy versus concurrent chemoradiation therapy [17,18,19,20,21,22]. …”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Chemoradiation Therapy versus Chemotherapy Alone for Gastric Cancer after R0 Surgical Resection: A Meta-Analysis of Randomized Trials

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Several small, probably underpowered studies have investigated the addition of radiotherapy to adjuvant 5-FU or cisplatin-based chemotherapy after D2 resection without demonstrating any significant benefit. 18,19 The role of radiotherapy after optimal surgery will be established by the results of the Korean ARTIST study of adjuvant chemotherapy compared with adjuvant chemoradiation after D2 resection, which are expected shortly. Although postoperative chemoradiotherapy is commonly practiced in US, it has not gained wider acceptance in Europe or Asia.…”

Section: Adjuvant Chemoradiotherapymentioning

confidence: 99%

Targeting HER-2 in gastric cancer – incorporation of trastuzumab into the treatment of operable disease

Bystrický¹,

Okines²,

Cunningham

2011

GICTT

View full text Add to dashboard Cite

Gastric cancer is the fourth most common malignancy and second leading cause of cancer death world-wide, and is therefore a significant global health problem. Radical surgery with a D2 lymph node dissection is an accepted standard approach, and is a key component of multimodality therapy. Perioperative chemotherapy significantly improves 5-year overall survival compared with surgery alone. A significant improvement in overall survival has also been demonstrated with postoperative 5-fluorouracil-based chemoradiotherapy and adjuvant oral S-1 chemotherapy; approaches commonly used widely in North America and Japan, respectively. Approximately 10% to 20% of gastric cancers and 20% to 30% of esophago-gastric junction cancers are HER-2 positive. The effect of HER-2 overexpression and HER-2 gene amplification on gastric cancer prognosis remains unresolved. The results of the first randomized phase III trial of trastuzumab, a monoclonal antibody directed at the HER-2 receptor, in patients with metastatic gastric cancer were reported recently. Response rate, median progression-free survival, and median overall survival were all significantly improved with the addition of trastuzumab to a cisplatin/fluoropyrimidine doublet. Evaluation of trastuzumab in HER-2 positive operable esophago-gastric cancer is now underway. Lapatinib, a small-molecule inhibitor targeting EGFR and HER-2 is well established in the treatment of trastuzumab-refractory HER-2 positive breast cancer and phase III trials in advanced esophago-gastric cancers are ongoing. Novel, small molecule pan-HER inhibitors have entered early phase evaluation and the antibody-drug conjugate, trastuzumab-DM1, and pertuzumab, a monoclonal antibody which prevents HER-2/ HER-3 dimerization, are currently undergoing phase II/III evaluation in breast cancer. It is our hope that advances in the targeted treatment of HER-2 positive breast cancer will be replicated in HER-2 positive esophago-gastric cancers.

show abstract

Retracted: Chemoresistance in gastric cancer is attributed to the overexpression of excision repair cross‐complementing 1 (ERCC1) caused by microRNA‐122 dysregulation

Song

Zhao

Wang

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

MicroRNAs are deemed as key regulators of gene expression. In particular, the elevated expression of excision repair cross-complementing 1 (ERCC1) significantly reduced the effectiveness of gastric cancer treatment by cisplatin (CDDP)-based therapies. In this paper, qRT-PCR and western blot were adopted to measure miR-122 and ERCC1 messenger RNA (mRNA) expression in all samples. Luciferase assay was carried out to verify the role of ERCC1 as a target of miR-122. The CCK-8 assay was carried out to study the effect of ERCC1 and miR-122 on cell survival and apoptosis. The results demonstrated that miR-122 expression was reduced in cisplatin-resistant gastric cancer. Using bioinformatic analysis, miR-122 was shown to target the 3′-UTR of human ERCC1. A dual-luciferase assay demonstrated that miR-122 downregulated ERCC1 expression, while the mutations in ERCC1 3′-UTR abolished its interaction with miR-122. Transfection of miR-122 mimics decreased the levels of ERCC1 mRNA and protein expression, while the transfection of miR-122 inhibitors increased the levels of both ERCC1 mRNA and protein expression. Furthermore, we found that overexpressed miR-122 promoted the proliferation of MKN74 cells and reduced their apoptotic by targeting ERCC1. In addition, the levels of miR-122 and ERCC1 were negatively correlated in gastric cancer samples. In summary, the reduced miR-122 expression may play an essential role in the induction of cisplatin-resistance by increasing ERCC1 expression. K E Y W O R D S apoptosis, chemoresistance, ERCC1, gastric cancer, microRNA-122, proliferation

show abstract

Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection

Abstract: We could not make any conclusion about the benefit of adding radiation to adjuvant chemotherapy.

Cited by 55 publications

References 19 publications

Chemoradiation Therapy versus Chemotherapy Alone for Gastric Cancer after R0 Surgical Resection: A Meta-Analysis of Randomized Trials

Chemoradiation Therapy versus Chemotherapy Alone for Gastric Cancer after R0 Surgical Resection: A Meta-Analysis of Randomized Trials

Targeting HER-2 in gastric cancer – incorporation of trastuzumab into the treatment of operable disease

Retracted: Chemoresistance in gastric cancer is attributed to the overexpression of excision repair cross‐complementing 1 (ERCC1) caused by microRNA‐122 dysregulation

Contact Info

Product

Resources

About

Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection

Abstract: We could not make any conclusion about the benefit of adding radiation to adjuvant chemotherapy.

Cited by 55 publications

References 19 publications

Chemoradiation Therapy versus Chemotherapy Alone for Gastric Cancer after R0 Surgical Resection: A Meta-Analysis of Randomized Trials

Chemoradiation Therapy versus Chemotherapy Alone for Gastric Cancer after R0 Surgical Resection: A Meta-Analysis of Randomized Trials

Targeting HER-2 in gastric cancer &ndash; incorporation of trastuzumab into the treatment of operable disease

Retracted: Chemoresistance in gastric cancer is attributed to the overexpression of excision repair cross‐complementing 1 (ERCC1) caused by microRNA‐122 dysregulation

Contact Info

Product

Resources

About

Targeting HER-2 in gastric cancer – incorporation of trastuzumab into the treatment of operable disease